Projected Earnings Analysis for Quarter 2 of 2025 by Niagen Bioscience
Niagen Bioscience Continues to Outperform with Q2 2025 Results
Niagen Bioscience (NASDAQ: NAGE) has once again demonstrated its financial strength, beating earnings and revenue estimates for the second quarter of 2025. The biotech company reported earnings of $0.09 per share, substantially surpassing analysts' expectations of $0.02 per share by an impressive 350%.
Revenue for Q2 2025 also exceeded expectations, coming in at $31.12 million compared to the consensus estimate of $28.55 million. This marks a significant beat of 10.2%.
Ingredient revenue showed particularly strong growth, increasing by 135% year-over-year to $7.4 million in Q2 2025.
The strong financial performance in Q2 2025 follows a similarly impressive first quarter, which saw 38% sales growth and increased margins. This growth has led to raised earnings per share estimates for 2025 and 2026.
Analysts have taken note of Niagen Bioscience's consistent quarterly growth and have responded by raising their price targets. Many maintain "buy" or "outperform" ratings, reflecting their confidence in the company's continued earnings and revenue momentum.
On Wednesday, August 6th, Niagen Bioscience will announce its Q2 results. The announcement will be made after market close on this date. It is expected that the stock market will be closed during this time.
Following the earnings announcement, analysts' reactions and potential revisions to their estimates for future quarters will be closely watched. The stock price may experience volatility as a result.
As of the current news, the earnings per share (EPS) consensus estimate for Q2 stands at $0.01. The consensus revenue estimate for Q2 is $28.31 million, indicating a year-over-year (Y/Y) increase of 24.7%.
The Q2 revenue estimate represents a significant growth for Niagen Bioscience, continuing the company's track record of consistently beating both earnings and revenue estimates over the last year.
Business analysts have revised their price targets for Niagen Bioscience (NASDAQ: NAGE) due to the company's impressive Q2 2025 financial results, substantially exceeding estimates. The strong performance in finance, especially in investing in ingredients, has led to increased expectations for 2025 and 2026.
Investors should closely watch the stock market's response after the Q2 results announcement on August 6th, as the stock price may exhibit volatility following the announcement and any revisions to future quarter estimates by analysts.
